controlled-release mitochondrial protonophore reverses diabetes steatohepatitis rats 
nonalcoholic fatty liver disease nafld major factor pathogenesis type diabetes t2d nonalcoholic steatohepatitis nash mitochondrial protonophore dinitrophenol dnp beneficial effects nafld insulin resistance obesity preclinical models toxic clinical use developed controlled-release oral formulation dnp called crmp controlled-release mitochondrial protonophore produces mild hepatic mitochondrial uncoupling rat models crmp reduced hypertriglyceridemia insulin resistance hepatic steatosis diabetes also normalized plasma transaminase concentrations ameliorated liver fibrosis improved hepatic protein synthetic function methionine/choline-deficient rat model nash chronic treatment crmp associated systemic toxicity data offer proof concept mild hepatic mitochondrial uncoupling may safe effective therapy related epidemics metabolic syndrome t2d nash 
